^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | RMC-6236 (RAS inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor
Published date:
01/18/2022
Excerpt:
Here, we demonstrate that single agent RMC-6236...is highly efficacious in preclinical models of KRAS mutant PDAC...Daily dosing of RMC-6236 drives profound and durable tumor regressions in multiple cell line derived (CDX) and patient derived (PDX) xenograft models of KRAS mutant PDAC...
DOI:
10.1200/JCO.2022.40.4_suppl.480
